AnaptysBio Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" AnaptysBio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANAB, but not buy additional shares or sell existing shares.
View analyst ratings for AnaptysBio or view top-rated stocks.

3 Wall Street analysts have issued 1 year price objectives for AnaptysBio's shares. Their ANAB stock forecasts range from $33.00 to $46.00. On average, they expect AnaptysBio's share price to reach $39.50 in the next twelve months. This suggests a possible upside of 93.0% from the stock's current price.
View analysts' price targets for AnaptysBio or view top-rated stocks among Wall Street analysts.

AnaptysBio's stock was trading at $34.75 at the start of the year. Since then, ANAB stock has decreased by 41.1% and is now trading at $20.47.
View the best growth stocks for 2022 here.

AnaptysBio is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for AnaptysBio.

AnaptysBio, Inc. (NASDAQ:ANAB) announced its quarterly earnings results on Wednesday, May, 4th. The biotechnology company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($0.87) by $0.44. The biotechnology company earned $0.97 million during the quarter, compared to analysts' expectations of $8.08 million. AnaptysBio had a negative net margin of 143.46% and a negative trailing twelve-month return on equity of 20.44%.
View AnaptysBio's earnings history.

Some companies that are related to AnaptysBio include Arvinas (ARVN), EQRx (EQRX), Global Blood Therapeutics (GBT), Schrödinger (SDGR), Sage Therapeutics (SAGE), ChemoCentryx (CCXI), Arcus Biosciences (RCUS), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Amphastar Pharmaceuticals (AMPH), Xencor (XNCR), Dynavax Technologies (DVAX), Xenon Pharmaceuticals (XENE), Aurinia Pharmaceuticals (AUPH) and Emergent BioSolutions (EBS).
View all of ANAB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Amarin (AMRN), Editas Medicine (EDIT), Illumina (ILMN), Clovis Oncology (CLVS), Twilio (TWLO) and AbbVie (ABBV).

(ANAB) raised $60 million in an initial public offering on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANAB stock can currently be purchased for approximately $20.47.

AnaptysBio (NASDAQ:ANAB) has a market capitalization of $576.97 million and generates $63.17 million in revenue each year. The biotechnology company earns $-57.80 million in net income (profit) each year or ($2.75) on an earnings per share basis.

AnaptysBio employs 102 workers across the globe.

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The official website for AnaptysBio is www.anaptysbio.com. The biotechnology company can be reached via phone at (858) 362-6295 or via email at investors@anaptysbio.com.